RECBIO-B (02179) has announced its interim results, showing a loss attributable to equity holders of approximately 212 million yuan, a year-on-year narrowing of 37.82%.

RECBIO-B (02179) announced its mid-term results for 2026, with revenue of approximately 47,000 yuan, a year-on-year decrease of 99.57%; the loss attributable to the equity holders of the parent company was approximately 212 million yuan, a year-on-year reduction of 37.82%; and a loss per share of 0.34 yuan. The announcement stated that the decrease in revenue was mainly due to the recognition of 10.8 million yuan in revenue from intellectual property licensing granted in the previous period. Similar licensing activities are underway in the current reporting period but have yet to meet the conditions for revenue recognition.